HQ: Washington DC
Founded: 1965, as OXIS International, Inc Name change in 2017.
GT Biopharma is a clinical-stage biopharmaceutical company, focused on developing immuno-oncology products from proprietary technology. This is a hot area of medical research that could be very profitable for a company to find an effective product. It has numerous product candidates. It also develops drug candidates for the central nervous system.
Market Cap: $107 million
Enterprise Value: $110 million
# of employees: 5
GT does not yet have marketable products or markets.
Production: They do not yet produce or sell any drug for the market.
Distribution: GT does not yet have marketable products. If and when it does, it will distribute in the US first.
Should you invest in GT Biopharma – GTBP (OTC)? Recommendation: See Below
Financials: Weak (no revenue yet)
CEO: Raymond W. Urbanski
Vice-Chair, Pres of Neurology: Kathleen Clarence-Smith
CFO: Steven W. Weldon
Director/ Consultant: Anthony J. Cataldo
VP of Finance: David Cardino
Current share price: $2.15
Price to Sales: NA (No revenue)
All cannabis-related stocks are risky due to the newness of the market. This company bears extra risk because it does not yet have products or revenue.
GT Biopharma is sometimes listed as a company doing research in the CBD related area. We do not see mention on their website of their product candidates being derived from CBD. We did find that the CEO, Mr. Urbanski, is on the Board of Directors of Damien Marley’s cannabis company, Stony Hill (OTC: STNY). This may be why GT Biopharma is sometimes listed as a company doing CBD related research.
About Cannin: Cannabis and Hemp Investment Experts
Market analysts expect the cannabis and hemp industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in cannabis and hemp stocks is now! Are you looking to buy stock in hemp companies or cannabis companies? Interested in emerging penny pot stock companies? Looking for the best Canadian pot company to invest in? Cannin is your trusted resource for information about Cannabis and Hemp stock investment opportunities. Our global team of experts evaluates emerging cannabis stock investing companies. We aggregate hundreds of hours of research and distill it down to make it easy for our investors to understand. We provide tips on the best cannabis and hemp stock investments for 2020. We provide the latest hemp investment news and analysis. Visit our site for cannabis investing news and featured companies, sign up for the free Cannin Chronicle or get a free trial of our smart cannabis and hemp stock algorithm to take the guesswork out of profiting from this exciting industry. Predict the price of cannabis and hemp stocks hours in advance with our machine learning algorithm. Is it too late to invest in marijuana? No! This is the perfect time.
Profit from the best Cannabis and Hemp stocks – we’ll show you how at cannin.com